https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveil...
If we knew how to do this, but valid patents blocked the broader commercialization of it, then we would not be reading stories about breakthroughs in basic implementations. We’d be reading stories about how companies have products ready to go once the countdown timer hits zero.
That's not 100% true, at least for the US:
https://slate.com/technology/2018/05/the-thousands-of-secret...
So, pharma companies trying to obtain "non-invasive glucose monitoring" patents like crazy, to stop other companies from creating such things, because they want to keep selling pinpricks which rely on a consumable model.
Having said that, now that everyone's into "bullshit subscription models", perhaps the era of "bullshit consumables" may be coming to an end.
up until now there has been zero financial incentive for stakeholders to promote a method of blood glucose measurement which bypasses the need for consumables, and every incentive to prevent such a solution.